PGR and metastatic malignant neoplasm in the lymph nodes: Furthermore, our analysis identified that younger patients (<60 years), those with negative PR expression, higher Ki67 expression levels, and absence of lymph node metastasis were more likely to respond to pyrotinib treatment.